The emerging roles of neuroactive components produced by gut microbiota DOI
Mitra Ansari Dezfouli,

Seyed Khalil Rashidi,

Nada Yazdanfar

et al.

Molecular Biology Reports, Journal Year: 2024, Volume and Issue: 52(1)

Published: Nov. 21, 2024

Language: Английский

The role of gut-derived short-chain fatty acids in Parkinson's disease DOI
Mohamed J. Saadh,

Anfal Nabeel Mustafa,

Mohammed Ahmed Mustafa

et al.

Neurogenetics, Journal Year: 2024, Volume and Issue: 25(4), P. 307 - 336

Published: Sept. 13, 2024

Language: Английский

Citations

2
The Vagus Nerve and the Brain-Gut Axis: Implications for Neuropsychiatric Disorders DOI

Wilfredo López-Ojeda,

Robin A. Hurley

Journal of Neuropsychiatry, Journal Year: 2024, Volume and Issue: 36(4), P. 278 - 282

Published: Oct. 1, 2024

Language: Английский

Citations

2
The Complex Relationship Between Gut Microbiota and Alzheimer’s Disease: A Systematic Review DOI Creative Commons

Xuan-Peng Zhou,

Lei Sun, Wenhao Liu

et al.

Ageing Research Reviews, Journal Year: 2024, Volume and Issue: unknown, P. 102637 - 102637

Published: Dec. 1, 2024

Alzheimer's disease (AD) is a progressive, degenerative disorder of the central nervous system. Despite extensive research conducted on this disorder, its precise pathogenesis remains unclear. In recent years, microbiota-gut-brain axis has attracted considerable attention within field AD. The gut microbiota communicates bidirectionally with system through gut-brain axis, and alterations in structure function can influence progression Consequently, regulating to mitigate AD emerged as novel therapeutic approach. Currently, numerous studies concentrate intrinsic relationship between paper, we summarize multifaceted role present detailed strategies targeting microbiota, including treatment Traditional Chinese Medicine (TCM), which garnered increasing years. Finally, discuss potential for modulating alleviate AD, current challenges area research, provide an outlook future directions field.

Language: Английский

Citations

2
IUPHAR Themed Review: The Gut Microbiome in Schizophrenia DOI Creative Commons
Srinivas Kamath,

Elysia Sokolenko,

Kate Collins

et al.

Pharmacological Research, Journal Year: 2024, Volume and Issue: unknown, P. 107561 - 107561

Published: Dec. 1, 2024

Gut microbial dysbiosis or altered gut consortium, in schizophrenia suggests a pathogenic role through the gut-brain axis, influencing neuroinflammatory and neurotransmitter pathways critical to psychotic, affective, cognitive symptoms. Paradoxically, conventional psychotropic interventions may exacerbate this dysbiosis, with antipsychotics, particularly olanzapine, demonstrating profound effects on architecture disruption of bacterial phyla ratios, diminished taxonomic diversity, attenuated short-chain fatty acid synthesis. To address these challenges, novel therapeutic strategies targeting microbiome, encompassing probiotic supplementation, prebiotic compounds, faecal microbiota transplantation, rationalised co-pharmacotherapy, show promise attenuating antipsychotic-induced metabolic disruptions while enhancing efficacy. Harnessing such insights, precision medicine approaches transform antipsychotic prescribing practices by identifying patients at risk side based their profiles. This IUPHAR review collates current literature landscape axis its intricate relationship advocating for integrating microbiome assessments management. Such fundamental shift proposing microbiome-informed prescriptions optimise efficacy reduce adverse impacts would align treatments safety, prioritising 'gut-neutral' gut-favourable drugs safeguard long-term patient outcomes therapy.

Language: Английский

Citations

2
The emerging roles of neuroactive components produced by gut microbiota DOI
Mitra Ansari Dezfouli,

Seyed Khalil Rashidi,

Nada Yazdanfar

et al.

Molecular Biology Reports, Journal Year: 2024, Volume and Issue: 52(1)

Published: Nov. 21, 2024

Language: Английский

Citations

1